Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of six patents by the Intellectual Property Department in Hong Kong. These patents cover proprietary combination therapies integrating Palmitoylethanolamide (PEA), sourced through the Company's partnership with NeuroThera Labs Inc. (TSXV:NTLX), with leading classic and innovative psychedelic compounds.

The published patents protect innovative synergistic formulations combining PEA with each of the following: 3,4-Methylenedioxymethamphetamine (MDMA), Lysergic Acid Diethylamide (LSD), Ketamine, Ibogaine, Psilocybin, and N,N-Dimethyltryptamine (DMT). These novel combinations aim to enhance therapeutic potential while potentially improving safety, tolerability, and neuroplasticity profiles for various mental health and neurological indications.